-
1
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med. 2015;373(22):2117-28.
-
(2015)
New Engl J Med
, vol.373
, Issue.22
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
Mattheus, M.7
Devins, T.8
Johansen, O.E.9
Woerle, H.J.10
-
2
-
-
84980320178
-
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
-
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-72.
-
(2016)
Circulation
, vol.134
, Issue.10
, pp. 752-772
-
-
Heerspink, H.J.1
Perkins, B.A.2
Fitchett, D.H.3
Husain, M.4
Cherney, D.Z.5
-
3
-
-
85023777061
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med. 2017;377(7):644-57.
-
(2017)
New Engl J Med
, vol.377
, Issue.7
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
Zeeuw, D.4
Fulcher, G.5
Erondu, N.6
Shaw, W.7
Law, G.8
Desai, M.9
Matthews, D.R.10
-
4
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-82.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.4
, pp. 372-382
-
-
Stenlof, K.1
Cefalu, W.T.2
Kim, K.A.3
Alba, M.4
Usiskin, K.5
Tong, C.6
Canovatchel, W.7
Meininger, G.8
-
5
-
-
84898791440
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
-
Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-77.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.5
, pp. 467-477
-
-
Forst, T.1
Guthrie, R.2
Goldenberg, R.3
Yee, J.4
Vijapurkar, U.5
Meininger, G.6
Stein, P.7
-
6
-
-
84930844091
-
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
-
Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-11.
-
(2015)
Diabetes Care
, vol.38
, Issue.3
, pp. 403-411
-
-
Neal, B.1
Perkovic, V.2
Zeeuw, D.3
Mahaffey, K.W.4
Fulcher, G.5
Ways, K.6
Desai, M.7
Shaw, W.8
Capuano, G.9
Alba, M.10
-
7
-
-
85017368135
-
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
-
Karagiannis T, Bekiari E, Tsapas A. Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evid. 2017;12:1-10.
-
(2017)
Core Evid
, vol.12
, pp. 1-10
-
-
Karagiannis, T.1
Bekiari, E.2
Tsapas, A.3
-
8
-
-
84975318811
-
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
-
Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.
-
(2016)
Cardiovasc Diabetol
, vol.15
, pp. 89
-
-
Inagaki, N.1
Harashima, S.2
Maruyama, N.3
Kawaguchi, Y.4
Goda, M.5
Iijima, H.6
-
9
-
-
85025091208
-
Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes
-
Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704-12.
-
(2017)
J Am Coll Cardiol
, vol.70
, Issue.6
, pp. 704-712
-
-
Januzzi, J.L.1
Butler, J.2
Jarolim, P.3
Sattar, N.4
Vijapurkar, U.5
Desai, M.6
Davies, M.J.7
-
10
-
-
85024835007
-
SGTL2 inhibitors and amputations in the US FDA adverse event reporting system
-
Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol. 2017;5(9):680-1.
-
(2017)
Lancet Diabetes Endocrinol
, vol.5
, Issue.9
, pp. 680-681
-
-
Fadini, G.P.1
Avogaro, A.2
-
11
-
-
84859021291
-
Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988-2008
-
Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988-2008. Diabetes Care. 2012;35(2):273-7.
-
(2012)
Diabetes Care
, vol.35
, Issue.2
, pp. 273-277
-
-
Li, Y.1
Burrows, N.R.2
Gregg, E.W.3
Albright, A.4
Geiss, L.S.5
-
12
-
-
84950119656
-
Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the fremantle diabetes study
-
Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the fremantle diabetes study. Cardiovasc Diabetol. 2015;14:152.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 152
-
-
Baba, M.1
Davis, W.A.2
Norman, P.E.3
Davis, T.M.4
-
13
-
-
85026909566
-
In-hospital costs of diabetic foot disease treated by a multidisciplinary foot team
-
Rinkel WD, Luiten J, van Dongen J, Kuppens B, Van Neck JW, Polinder S, Castro Cabezas M, Coert JH. In-hospital costs of diabetic foot disease treated by a multidisciplinary foot team. Diabetes Res Clin Pract. 2017;132:68-78.
-
(2017)
Diabetes Res Clin Pract
, vol.132
, pp. 68-78
-
-
Rinkel, W.D.1
Luiten, J.2
Dongen, J.3
Kuppens, B.4
Neck, J.W.5
Polinder, S.6
Castro Cabezas, M.7
Coert, J.H.8
-
14
-
-
84886719687
-
Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study
-
Winell K, Venermo M, Ikonen T, Sund R. Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study. Eur J Vasc Endovasc Surg. 2013;46(5):569-74.
-
(2013)
Eur J Vasc Endovasc Surg
, vol.46
, Issue.5
, pp. 569-574
-
-
Winell, K.1
Venermo, M.2
Ikonen, T.3
Sund, R.4
-
15
-
-
61849115759
-
Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations
-
Johannesson A, Larsson GU, Ramstrand N, Turkiewicz A, Wirehn AB, Atroshi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care. 2009;32(2):275-80.
-
(2009)
Diabetes Care
, vol.32
, Issue.2
, pp. 275-280
-
-
Johannesson, A.1
Larsson, G.U.2
Ramstrand, N.3
Turkiewicz, A.4
Wirehn, A.B.5
Atroshi, I.6
-
16
-
-
84984972641
-
Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
-
Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, Harrap S, Poulter N, Matthews DR, Marre M, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15(1):129.
-
(2016)
Cardiovasc Diabetol
, vol.15
, Issue.1
, pp. 129
-
-
Mohammedi, K.1
Woodward, M.2
Hirakawa, Y.3
Zoungas, S.4
Colagiuri, S.5
Hamet, P.6
Harrap, S.7
Poulter, N.8
Matthews, D.R.9
Marre, M.10
-
17
-
-
85026830716
-
Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study
-
Baubeta Fridh E, Andersson M, Thuresson M, Sigvant B, Kragsterman B, Johansson S, Hasvold P, Falkenberg M, Nordanstig J. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study. European J Vasc Endovasc Surg. 2017;54(4):480-6.
-
(2017)
European J Vasc Endovasc Surg
, vol.54
, Issue.4
, pp. 480-486
-
-
Baubeta Fridh, E.1
Andersson, M.2
Thuresson, M.3
Sigvant, B.4
Kragsterman, B.5
Johansson, S.6
Hasvold, P.7
Falkenberg, M.8
Nordanstig, J.9
-
18
-
-
85021054097
-
Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials
-
Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34(7):1707-26.
-
(2017)
Adv Ther
, vol.34
, Issue.7
, pp. 1707-1726
-
-
Kohler, S.1
Zeller, C.2
Iliev, H.3
Kaspers, S.4
-
19
-
-
85030843541
-
Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study
-
Yuan Z, DeFalco FJ, Ryan PB, Schuemie MJ, Stang PE, Berlin JA, Desai M, Rosenthal N. Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab. 2017. doi: 10.1111/dom.13115.
-
(2017)
Diabetes Obes Metab
-
-
Yuan, Z.1
DeFalco, F.J.2
Ryan, P.B.3
Schuemie, M.J.4
Stang, P.E.5
Berlin, J.A.6
Desai, M.7
Rosenthal, N.8
|